Skip to content

Subsyndromal Delirium in Intensive Care Unit

Subsyndromal Delirium in Intensive Care Unit, a Multicenter Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03813459
Acronym
SubSynD
Enrollment
400
Registered
2019-01-23
Start date
2018-08-01
Completion date
2020-03-31
Last updated
2021-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Keywords

Delirium, Subsyndromal delirium, Intensive Care Unit

Brief summary

Subsyndromal delirium (SSD) is a condition characterized by a less severe cognitive impairment in comparison to delirium. To date there is no published consensus on SSD definitions and has been commonly reported as an intermediate stage between delirium and normal mental states. SSD encompasses some of the delirium symptoms, and has been diagnosed with Intensive Care Delirium Screening Checklist scale (ICDSC) and Confusion Assessment Method-ICU (CAM-ICU). The objective of this study is to identify subsyndromal delirium prevalence, the association between SSD and clinical outcomes and understanding the relationship between SSD and conversion to delirium. The relevance of this study is understanding of subsyndromal delirium in ICU, namely the importance of early presentations of acute brain dysfunction in the patients outcome.

Detailed description

SubSynD is a prospective, observational, multicenter clinical study, involving 400 patients in Intensive Care Units, to assess subsyndromal delirium. A systematic screening for delirium and subsyndromal delirium (SSD) is done with Intensive Care Delirium Screening Checklist (ICDSC) and Confusion Assessment Method-ICU (CAM-ICU). Scales are applied once per day until ICU discharge or for up to 14 days of being in ICU. The investigators access three different groups of patients: non-delirium, delirium and subsyndromal delirium. It is intended that either ICDSC or CAM-ICU, paired with a Richmond Agitation and Sedation Scale (RASS) be administered once per day (i.e. with first assessment in the morning). All patients with abnormal CAM-ICU or ICDSC features, beside the underlying cause of delirium and SSD are included. In addition, data regarding baseline demographic and clinical characteristics will be collected as well as data regarding the procedure performed (see Case Report Form (CRF)).

Interventions

None listed

Sponsors

Orion Corporation, Orion Pharma
CollaboratorINDUSTRY
Centro Hospitalar Lisboa Ocidental
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years; 2. Admission in Intensive care Unit

Exclusion criteria

1. Primary neurological diagnosis, with Glasgow Coma Scale (GCS) \<14 on ICU admission or in previous days; 2. Blindness or deafness; 3. Aphasia; 4. Inability to communicate in the native language of the country where the study is enrolled; 5. Death during the first 24 hours; 6. Limitation of therapeutic efforts in the Intensive Care Unit admission; 7. Refusal to participate; 8. Previous diagnosis of dementia or psychiatric illness; 9. Readmission in ICU;

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with conversion from subsyndromal delirium to delirium during the period of study14 daysICDSC performed 1 time per day and determine how subsyndromal delirium (ICDSC 1-3) can have conversion to delirium (ICDSC \>/=4).
Mortality28 daysdefined as number of days that patients survived in 28 days
Ventilation free days28 daysdefined has the number of days from day 1 to day 28 on which a patient breathed without assistance

Secondary

MeasureTime frameDescription
ICU length of stay24 monthsdays until ICU discharge
Hospital length of stay24 monthsdays until ICU discharge

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026